All In Biotech

Drug Trial Radar · NCT05824065

Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss

Phase III, National, Multicenter, Randomized, Double-Blind, Superiority Clinical Trial to Evaluate the Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss

Last checked: Nov 19, 2026Latest source record: Feb 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 504 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

504

Planned (sponsor's estimate)

Start

Jan 2025

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
EMSIndustry
Sponsor type
Industry
First posted
Apr 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy and safety of OMA102 1 mg and OMA102 2 mg versus placebo in the treatment of female pattern hair loss.

Conditions

  • Female Pattern Baldness

Interventions

  • OMA102Drug

    1 mg

  • OMA102Drug

    2 mg

  • PlaceboDrug

    OMA102 - Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of OMA102 1 mg and OMA102 2 mg in the promotion of hair growth in the mid front area assessed by digital phototrichogram.Time frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • EMS

    Hortolândia, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.